Cancer Chemotherapy and Pharmacology

, Volume 72, Issue 3, pp 597–606 | Cite as

The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor

  • Michele Visentin
  • Ersin Selcuk Unal
  • Rongbao Zhao
  • I. David Goldman
Original Article

Abstract

Purpose

To characterize, directly and for the first time, the membrane transport and metabolism of pralatrexate, a new-generation dihydrofolate reductase inhibitor approved for the treatment for peripheral T-cell lymphoma.

Experimental design

[3H]pralatrexate transport was studied in unique HeLa cell lines that express either the reduced folate carrier (RFC) or the proton-coupled folate transporter (PCFT). Metabolism to active polyglutamate derivatives was assessed by liquid chromatography. These properties were compared to those of methotrexate (MTX).

Results

The pralatrexate influx K t, mediated by RFC, the major route of folate/antifolate transport at systemic pH, was 0.52 μΜ, 1/10th the MTX influx K i. The electrochemical potential of pralatrexate within HeLa cells far exceeded the extracellular level and was greater than for MTX. In contrast, MTX transport mediated by PCFT, the mechanism of folate/antifolate absorption in the small intestine, exceeded that for pralatrexate. After a 6 h exposure of HeLa cells to 0.5 μM pralatrexate, 80 % of intracellular drug was its active polyglutamate forms, predominantly the tetraglutamate, and was suppressed when cells were loaded with natural folates. There was negligible formation of MTX polyglutamates. The difference in pralatrexate and MTX growth inhibition was far greater after transient exposures (375-fold) than continuous exposure (25-fold) to the drugs.

Conclusions

Pralatrexate’s enhanced activity relative to MTX is due to its much more rapid rate of transport and polyglutamation, the former less important when the carrier is saturated. The low affinity of pralatrexate for PCFT predicts a lower level of enterohepatic circulation and increased fecal excretion of the drug relative to MTX.

Keywords

Methotrexate PCFT Polyglutamation Pralatrexate RFC 

Abbreviations

5-FormylTHF

(6S)5-Formyltetrahydrofolate

AICAR transformylase

Phosphoribosylaminoimidazole carboxamide formyltransferase

DHFR

Dihydrofolate reductase

FPGS

Folylpolyglutamate synthetase

MTX

Methotrexate

PCFT

Proton-coupled folate transporter

RFC

Reduced folate carrier

Notes

Acknowledgments

This study was supported by Spectrum Pharmaceutical (Irvine, CA) and a Grant from the National Institutes of Health National Cancer Institute [CA82621].

Conflict of interest

No conflict to disclose.

References

  1. 1.
    Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11:5–14PubMedGoogle Scholar
  2. 2.
    Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff VA (1948) Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N Engl J Med 238:787–793PubMedCrossRefGoogle Scholar
  3. 3.
    Osborn MJ, Huennekens FM (1958) Enzymatic reduction of dihydrofolic acid. J Biol Chem 233:969–974PubMedGoogle Scholar
  4. 4.
    Visentin M, Zhao R, Goldman ID (2012) The antifolates. Hematol Oncol Clin North Am 26:629–648PubMedCrossRefGoogle Scholar
  5. 5.
    Zhao R, Goldman ID (2003) Resistance to antifolates. Oncogene 22:7431–7457PubMedCrossRefGoogle Scholar
  6. 6.
    Baugh CM, Krumdieck CL, Nair MG (1973) Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 52:27–34PubMedCrossRefGoogle Scholar
  7. 7.
    Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907–912PubMedCrossRefGoogle Scholar
  8. 8.
    Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA (1985) Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 75:1008–1014PubMedCrossRefGoogle Scholar
  9. 9.
    Poser RG, Sirotnak FM, Chello PL (1981) Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res 41:4441–4446PubMedGoogle Scholar
  10. 10.
    Fabre I, Fabre G, Goldman ID (1984) Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 44:3190–3195PubMedGoogle Scholar
  11. 11.
    Allegra CJ, Fine RL, Drake JC, Chabner BA (1986) The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 261:6478–6485PubMedGoogle Scholar
  12. 12.
    Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J (1985) Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720–9726PubMedGoogle Scholar
  13. 13.
    Matherly LH, Barlowe CK, Goldman ID (1986) Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Res 46:588–593PubMedGoogle Scholar
  14. 14.
    Matherly LH, Barlowe CK, Phillips VM, Goldman ID (1987) The effects of 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. J Biol Chem 262:710–717PubMedGoogle Scholar
  15. 15.
    Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M, Moran RG (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450–4454PubMedCrossRefGoogle Scholar
  16. 16.
    Racanelli AC, Rothbart SB, Heyer CL, Moran RG (2009) Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69:5467–5474PubMedCrossRefGoogle Scholar
  17. 17.
    Piper JR, Johnson CA, Otter GM, Sirotnak FM (1992) Synthesis and antifolate evaluation of 10-ethyl-5-methyl- 5,10-dideazaaminopterin and an alternative synthesis of 10-ethyl-10-deazaaminopterin (edatrexate). J Med Chem 35:3002–3006PubMedCrossRefGoogle Scholar
  18. 18.
    Sirotnak FM, DeGraw JI, Colwell WT, Piper JR (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42:313–318PubMedCrossRefGoogle Scholar
  19. 19.
    Sirotnak FM, DeGraw JI, Schmid FA, Goutas LJ, Moccio DM (1984) New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 12:26–30PubMedGoogle Scholar
  20. 20.
    O’Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27:4357–4364PubMedCrossRefGoogle Scholar
  21. 21.
    O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 20;29:1182–1189Google Scholar
  22. 22.
    Zhao R, Diop-Bove N, Visentin M, Goldman ID (2011) Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 31:177–201PubMedCrossRefGoogle Scholar
  23. 23.
    Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917–928PubMedCrossRefGoogle Scholar
  24. 24.
    Zhao R, Babani S, Gao F, Liu L, Goldman ID (2000) The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 6:3687–3695PubMedGoogle Scholar
  25. 25.
    Zhao R, Gao F, Hanscom M, Goldman ID (2004) A prominent low-pH methotrexate transport activity in human solid tumor cells: contribution to the preservation of methotrexate pharmacological activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718–727PubMedCrossRefGoogle Scholar
  26. 26.
    Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID (2008) The proton-coupled folate transporter (PCFT): impact on pemetrexed transport and on antifolate activities as compared to the reduced folate carrier. Mol Pharmacol 74:854–862PubMedCrossRefGoogle Scholar
  27. 27.
    Diop-Bove NK, Wu J, Zhao R, Locker J, Goldman ID (2009) Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. Mol Cancer Ther 8:2424–2431PubMedCrossRefGoogle Scholar
  28. 28.
    Visentin M, Zhao R, Goldman ID (2012) Augmentation of reduced folate carrier-mediated transport of folates/antifolates through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphate. Mol Pharmacol 82:209–216PubMedCrossRefGoogle Scholar
  29. 29.
    Zhao R, Chattopadhyay S, Hanscom M, Goldman ID (2004) Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Clin Cancer Res 10:8735–8742PubMedCrossRefGoogle Scholar
  30. 30.
    Sharif KA and Goldman ID (2000) Rapid determination of membrane transport parameters in adherent cells. BioTechniques 28:926–928, 930, 932Google Scholar
  31. 31.
    Goldman ID, Lichtenstein NS, Oliverio VT (1968) Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell. J Biol Chem 243:5007–5017PubMedGoogle Scholar
  32. 32.
    Zhao R, Hanscom M, Chattopadhyay S, Goldman ID (2004) Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Res 64:3313–3319PubMedCrossRefGoogle Scholar
  33. 33.
    Zhao R, Gao F, Goldman ID (2001) Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 61:857–865PubMedCrossRefGoogle Scholar
  34. 34.
    Desmoulin SK, Hou Z, Gangjee A, Matherly LH (2012) The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol Ther 13:1355–1373PubMedCrossRefGoogle Scholar
  35. 35.
    Matherly LH, Voss MK, Anderson LA, Fry DW, Goldman ID (1985) Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro. Cancer Res 45:1073–1078PubMedGoogle Scholar
  36. 36.
    Ratliff AF, Wilson J, Hum M, Marling-Cason M, Rose K, Winick N, Kamen BA (1998) Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 16:1458–1464PubMedGoogle Scholar
  37. 37.
    Khokhar NZ, She Y, Rusch VW, Sirotnak FM (2001) Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Clin Cancer Res 7:3199–3205PubMedGoogle Scholar
  38. 38.
    Wang ES, O’Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA (2003) Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44:1027–1035PubMedCrossRefGoogle Scholar
  39. 39.
    Zhao R, Seither R, Brigle KE, Sharina IG, Wang PJ, Goldman ID (1997) Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. J Biol Chem 272:21207–21212PubMedCrossRefGoogle Scholar
  40. 40.
    Ehrenberg B, Montana V, Wei MD, Wuskell JP, Loew LM (1988) Membrane potential can be determined in individual cells from the nernstian distribution of cationic dyes. Biophys J 53:785–794PubMedCrossRefGoogle Scholar
  41. 41.
    Stein MA, Mathers DA, Yan H, Baimbridge KG, Finlay BB (1996) Enteropathogenic Escherichia coli markedly decreases the resting membrane potential of Caco-2 and HeLa human epithelial cells. Infect Immun 64:4820–4825PubMedGoogle Scholar
  42. 42.
    Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, Sirotnak F, Fleisher M, Saunders ME, O’Connor OA (2009) A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin’s or Hodgkin’s lymphoma. Clin Pharmacol Ther 86:190–196PubMedCrossRefGoogle Scholar
  43. 43.
    Steinberg SE, Campbell CL, Bleyer WA, Hillman RS (1982) Enterohepatic circulation of methotrexate in rats in vivo. Cancer Res 42:1279–1282PubMedGoogle Scholar
  44. 44.
    Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV (2009) Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27:5972–5978PubMedCrossRefGoogle Scholar
  45. 45.
    Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, Evans WE, Hunger SP, Loh M, Relling MV (2013) Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121:898–904PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Michele Visentin
    • 1
  • Ersin Selcuk Unal
    • 2
  • Rongbao Zhao
    • 1
    • 3
  • I. David Goldman
    • 1
    • 3
  1. 1.Department of Molecular PharmacologyAlbert Einstein College of MedicineBronxUSA
  2. 2.Department of Medicine, Jacobi Medical CenterAlbert Einstein College of MedicineBronxUSA
  3. 3.Department of MedicineAlbert Einstein College of MedicineBronxUSA

Personalised recommendations